Screening collections play a pivotal role in drug discovery, offering a diverse range of compounds that enable the efficient identification of potential drug candidates. By saving time and resources, these collections streamline the discovery process, reduce costs, and increase the likelihood of finding effective and innovative drugs.
The Legacy Screening Collection, the result of 15 years of successful collaboration between Enamine and UORSY, features over 1.76 million in-stock compounds used in high-throughput screening for drug discovery. Legacy compounds are synthesized from in-house building blocks using carefully developed and optimized reactions.
Physicochemical Properties of the Discovery Diversity Sets:
• 79% drug-like compounds;• 53% lead-like compounds;
• 10% shaped molecules (8% disc & 2% sphere);
More than 50% of them possess drug-like physicochemical properties, while over 40% exhibit lead-like profiles.
The Legacy Screening Collection is now available in Discovery Diversity Set of 5,000 and 10,000 compounds, providing a comprehensive representation of this vast library at the most competitive prices on the market. These screening compounds from the stock are flexible in formatting, as they are not pre-plated, allowing customization according to the client's specifications.
For any questions contact us at sales@chem-space.com.
• 9% high QED;
• 2% PAINS;
• 1% fragment-like compounds.
